Reza Farzaneh

Reza Farzaneh

Auto-generated profile, based on publicly available information

Reza Farzaneh

Department of Nursing, Faculty of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2026 in Immunopathologia Persa
Verified
Journal Article
Closed access
ZKZahed Karimi
Zahed Karimi
SNSara Abutalebi Nasrabad
Sara Abutalebi Nasrabad
RFReza Farzaneh
Reza Farzaneh
SBSeyed Amir Banikarim
Seyed Amir Banikarim
FSFarkhondeh Sameipoor
Farkhondeh Sameipoor
NNNaeem Nikpour
Naeem Nikpour
The mechanistic sequence from hyperandrogenism to tumorigenesis in women with polycystic ovary syndrome (PCOS) encompasses a constellation of structural and functional aberrations spanning the endocrine, metabolic, immunologic, and genetic domains. Chronic hyperandrogenism incites an interconnected cascade through chronic anovulation and unopposed estrogen action, insulin resistance with hyperinsulinemia, low-grade systemic inflammation, oxidative stress, and gut dysbiosis, each playing a synergistic role in promoting oncogenesis. It has been demonstrated that, this syndrome is most strongly associated with an increased risk of endometrial cancer, with a more modest and less consistent association with ovarian and breast cancers. Thyroid cancer risk may also be elevated, particularly in younger women. The underlying mechanisms involve hormonal imbalances, metabolic dysfunction, chronic inflammation, and genetic predisposition. Women with PCOS should be monitored for early signs of these cancers, and management should focus on mitigating risk factors such as obesity, insulin resistance, and chronic anovulation.

28 March 2026 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
NNNaeem Nikpour
Naeem Nikpour
RFReza Farzaneh
Reza Farzaneh
MDMohammad Mehdi Darzi
Mohammad Mehdi Darzi
SZSimin Zeinadini
Simin Zeinadini
SSSetare Sadeghi
Setare Sadeghi
RARasoul Jafari Arismani
Rasoul Jafari Arismani
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs like 177Lu-DOTATATE) is highly effective for metastatic neuroendocrine tumors (NETs). However, a significant dose-limiting toxicity is radiation-induced nephropathy, primarily driven by a phenomenon termed the proximal tubular trap. Following glomerular filtration, radiolabeled peptides are avidly reabsorbed by proximal tubular epithelial cells (PTECs) via the megalin/cubilin receptor-mediated endocytosis pathway. This intracellular retention concentrates the radionuclide within the tubules, leading to prolonged, localized irradiation of renal tissue, particularly the radiosensitive proximal tubules and microvasculature. Cumulative radiation exposure causes DNA damage, oxidative stress, inflammation, and ultimately progressive tubular atrophy, interstitial fibrosis, and glomerulosclerosis, manifesting clinically as declining glomerular filtration rate (GFR), proteinuria, and potentially end-stage renal disease months to several years post-therapy.